Clindamycin/tretinoin - Ortho Dermatologics

Drug Profile

Clindamycin/tretinoin - Ortho Dermatologics

Alternative Names: Acnatac; Acnex; CLin-RA; CLIN/RA Gel (1.2% clindamycin phosphate and crystalline 0.025% tretinoin aqueous gel) - Meda; Clindamycin/tretinoin gel - Meda; Tretinoin/clindamycin gel - Ortho Dermatologics; Ziana

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Meda
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 24 Sep 2015 Launched for Acne vulgaris in Denmark (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top